|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Heintz AP, Odicino F, Maisonneuve P, Quinn
MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S and Beller U:
Carcinoma of the ovary = FIGO 26th Annual Report on the Results of
Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 95(Suppl
1): S161–S192. 2006. View Article : Google Scholar
|
|
3
|
McGuire WP, Hoskins WJ, Brady MF, Kucera
PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M:
Cyclophosphamide and cisplatin compared with paclitaxel and
cisplatin in patients with stage III and stage IV ovarian cancer. N
Engl J Med. 334:1–6. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yokoyama Y, Xin B, Shigeto T, Umemoto M,
Kasai-Sakamoto A, Futagami M, Tsuchida S, Al-Mulla F and Mizunuma
H: Clofibric acid, a peroxisome proliferator-activated receptor α
ligand, inhibits growth of human ovarian cancer. Mol Cancer Ther.
6:1379–1386. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gonzalez-Covarrubias V, Ghosh D, Lakhman
SS, Pendyala L and Blanco JG: A functional genetic polymorphism on
human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic
activity and NADPH binding affinity. Drug Metab Dispos. 35:973–980.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wermuth B, Bohren KM, Heinemann G, von
Wartburg JP and Gabbay KH: Human carbonyl reductase. Nucleotide
sequence analysis of a cDNA and amino acid sequence of the encoded
protein. J Biol Chem. 263:16185–16188. 1988.PubMed/NCBI
|
|
7
|
Umemoto M, Yokoyama Y, Sato S, Tsuchida S,
Al-Mulla F and Saito Y: Carbonyl reductase as a significant
predictor of survival and lymph node metastasis in epithelial
ovarian cancer. Br J Cancer. 85:1032–1036. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Murakami A, Fukushima C, Yoshidomi K,
Sueoka K, Nawata S, Yokoyama Y, Tsuchida S, Ismail E, Al-Mulla F
and Sugino N: Suppression of carbonyl reductase expression enhances
malignant behaviour in uterine cervical squamous cell carcinoma:
Carbonyl reductase predicts prognosis and lymph node metastasis.
Cancer Lett. 311:77–84. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Murakami A, Yakabe K, Yoshidomi K, Sueoka
K, Nawata S, Yokoyama Y, Tsuchida S, Al-Mulla F and Sugino N:
Decreased carbonyl reductase 1 expression promotes malignant
behaviours by induction of epithelial mesenchymal transition and
its clinical significance. Cancer Lett. 323:69–76. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Osawa Y, Yokoyama Y, Shigeto T, Futagami M
and Mizunuma H: Decreased expression of carbonyl reductase 1
promotes ovarian cancer growth and proliferation. Int J Oncol.
46:1252–1258. 2015.PubMed/NCBI
|
|
11
|
Wang H, Yokoyama Y, Tsuchida S and
Mizunuma H: Malignant ovarian tumors with induced expression of
carbonyl reductase show spontaneous regression. Clin Med Insights
Oncol. 6:107–115. 2012.PubMed/NCBI
|
|
12
|
Hanayama R, Tanaka M, Miwa K, Shinohara A,
Iwamatsu A and Nagata S: Identification of a factor that links
apoptotic cells to phagocytes. Nature. 417:182–187. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
van Horssen R, Ten Hagen TL and Eggermont
AM: TNF-alpha in cancer treatment: Molecular insights, antitumor
effects, and clinical utility. Oncologist. 11:397–408. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tracey KJ and Cerami A: Tumor necrosis
factor, other cytokines and disease. Annu Rev Cell Biol. 9:317–343.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vandenabeele P, Declercq W, Beyaert R and
Fiers W: Two tumour necrosis factor receptors: Structure and
function. Trends Cell Biol. 5:392–399. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rath PC and Aggarwal BB: TNF-induced
signaling in apoptosis. J Clin Immunol. 19:350–364. 1999.
View Article : Google Scholar
|
|
17
|
Degterev A, Boyce M and Yuan J: A decade
of caspases. Oncogene. 22:8543–8567. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Barnes PJ and Karin M: Nuclear
factor-kappaB: A pivotal transcription factor in chronic
inflammatory diseases. N Engl J Med. 336:1066–1071. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Karin M, Liu Z and Zandi E: AP-1 function
and regulation. Curr Opin Cell Biol. 9:240–246. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rothe M, Pan M-G, Henzel WJ, Ayres TM and
Goeddel DV: The TNFR2-TRAF signaling complex contains two novel
proteins related to baculoviral inhibitor of apoptosis proteins.
Cell. 83:1243–1252. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shigeto T, Yokoyama Y, Xin B and Mizunuma
H: Peroxisome proliferator-activated receptor α and γ ligands
inhibit the growth of human ovarian cancer. Oncol Rep. 18:833–840.
2007.PubMed/NCBI
|
|
22
|
Wakui M, Yokoyama Y, Wang H, Shigeto T,
Futagami M and Mizunuma H: Efficacy of a methyl ester of
5-aminolevulinic acid in photodynamic therapy for ovarian cancers.
J Cancer Res Clin Oncol. 136:1143–1150. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cebulla J, Huuse EM, Pettersen K, van der
Veen A, Kim E, Andersen S, Prestvik WS, Bofin AM, Pathak AP,
Bjørkøy G, et al: MRI reveals the in vivo cellular and vascular
response to BEZ235 in ovarian cancer xenografts with different
PI3-kinase pathway activity. Br J Cancer. 112:504–513. 2015.
View Article : Google Scholar
|
|
24
|
Hirakawa H, Yokoyama Y, Yoshida H and
Mizunuma H: Inhibitory effects of aromatase inhibitor on estrogen
receptor-alpha positive ovarian cancer in mice. J Ovarian Res.
7:42014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
McFarlane SM, Pashmi G, Connell MC,
Littlejohn AF, Tucker SJ, Vandenabeele P and MacEwan DJ:
Differential activation of nuclear factor-kappaB by tumour necrosis
factor receptor subtypes. TNFR1 predominates whereas TNFR2
activates transcription poorly. FEBS Lett. 515:119–126. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wajant H, Pfizenmaier K and Scheurich P:
Tumor necrosis factor signaling. Cell Death Differ. 10:45–65. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Naudé PJ, den Boer JA, Luiten PG and Eisel
UL: Tumor necrosis factor receptor cross-talk. FEBS J. 278:888–898.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zerbini LF, Tamura RE, Correa RG, Czibere
A, Cordeiro J, Bhasin M, Simabuco FM, Wang Y, Gu X, Li L, et al:
Combinatorial effect of non-steroidal anti-inflammatory drugs and
NF-κB inhibitors in ovarian cancer therapy. PLoS One. 6:e242852011.
View Article : Google Scholar
|
|
29
|
Nishio H, Yaguchi T, Sugiyama J, Sumimoto
H, Umezawa K, Iwata T, Susumu N, Fujii T, Kawamura N, Kobayashi A,
et al: Immunosuppression through constitutively activated NF-κB
signalling in human ovarian cancer and its reversal by an NF-κB
inhibitor. Br J Cancer. 110:2965–2974. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Takano M, Sugiyama T, Yaegashi N, Sagae S,
Kuzuya K, Udagawa Y, Tsuda H, Suzuki M, Kigawa J, Goto T, et al:
Less impact of adjuvant chemotherapy for stage I clear cell
carcinoma of the ovary: A retrospective Japan Clear Cell Carcinoma
Study. Int J Gynecol Cancer. 20:1506–1510. 2010.PubMed/NCBI
|
